Pediococcus acidilactici

Quality 0.50 · 1 view · Updated 2 months ago

Species of bacterium

title: "Pediococcus acidilactici" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["lactobacillaceae", "bacteria-described-in-1887"] description: "Species of bacterium" topic_path: "general/lactobacillaceae" source: "https://en.wikipedia.org/wiki/Pediococcus_acidilactici" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Species of bacterium ::

| image = Pediococcus acidilactici on TSA.jpg | image_caption = Pediococcus acidilactici colonies on an MRS agar plate | genus = Pediococcus | species = acidilactici | authority = Lindner 1887 (Approved Lists 1980)

Pediococcus acidilactici is a species of Gram-positive cocci that is often found in pairs or tetrads. P. acidilactici is a homofermentative bacterium that can grow in a wide range of pH, temperature, and osmotic pressure, therefore being able to colonize the digestive tract. It has emerged as a potential probiotic that has shown promising results in animal and human experiments. However, some of the results are limited. They are commonly found in fermented vegetables, fermented dairy products, and meat.

Pediococcus acidilactici is a facultative anaerobe that grows well on de Man, Rogosa, Sharpe agar of an optimum pH of 6.2, with an overnight incubation at 37 and. It is also viable at higher temperatures up to 65 C.

This species is also acidophilic, and viable at very low pH. The probiotic P. acidilactici is a facultative anaerobe with lesser sensitivity to oxygen. Pediococci exert antagonism against other microorganisms, including enteric pathogens, primarily through the production of lactic acid and secretion of bacteriocins known as pediocins.

Potential benefits

Pediococcus acidilactici has a wide range of potential benefits which are still being studied. Though it is being used as a probiotic supplement to treat constipation, and diarrhea, relieve stress, and enhance immune response among birds and small animals, human trials are still limited. P. acidilactici is also known to prevent colonization of the small intestine by pathogens such as Shigella spp., Salmonella spp., Clostridioides difficile, and Escherichia coli among small animals.

Digestive disorders

Pediococcus acidilactici has been used to treat dogs with digestive disorders and those infected by parvovirus. Before treatment with orally administered mixtures of P. acidilactici and Saccharomyces boulardii, the dogs diagnosed with parvovirus infection were shown to exhibit severe gastrointestinal distress such as vomiting and bloody diarrhea. After the treatment for three days, the bloody diarrhea ceased and the dogs had solid stools.

Alternative medicine

Pediococcus acidilactici has not been stated in any literature to have toxic effects. Another potential benefit of using them as probiotics is their use as alternative medicines against infectious parasitic pathogens such as Eimeria in broiler chickens. P. acidilactici in conjunction with S. boulardii stimulates humoral immune response to produce higher Eimeria-specific antibody levels while also reducing the number of oocysts shed by possible competitive inhibition and pediocin production, which inhibit pathogenic bacteria and other Gram-positive spoilage.

Immune health benefits

Pediococcus acidilactici can function as an immune modulator. Animals fed with P. acidilactici have shown enhanced immune responses against infectious coccidioidal diseases.

Antibiotic treatment

Dogs typically undergo antibiotic treatment to eliminate infectious pathogens or parasites and to prevent secondary infections. However, the treatment with antibiotics can also disrupt the ecosystems of beneficial microorganisms in the dog's gastrointestinal (GI) tract. When dogs with digestive disorders were treated by antibiotics together with P. acidilactici probiotic products, the surviving millions of bacteria were able to alleviate the disrupted balance of microorganisms in dogs’ GI tracts caused by antibiotics treatment and to normalize the intestinal microflora.

Moreover, since antibiotics kill many of competitive pathogenic microorganisms, Pediococcus products can have better beneficial effects in dogs and cats' GI tracts when administered with antibiotics.

Difference from other probiotic strains

Most strains of Lactobacillus and Bifidobacterium are sensitive to room temperature, which raises concerns for storage conditions and maintenance of cell viability. In addition, most Lactobacillus and Bifidobacterium species are sensitive to acidic exposure and have difficulty surviving environments with low pH, such as stomach acid. Therefore, obtaining consistent and reproducible results becomes the major challenge for the commercial products of* Lactobacillus* and Bifidobacterium.

References

--

References

  1. Klaenhammer T.R. 1993. Genetics of bacteriocins produced by [[lactic acid bacteria]]. FEMS Microbiol. Rev. 12 :39S-85S
  2. Barros R.R., Carvalho G.S., Peralta J.M., Facklam R.R., Teixeira L.M. 2001. Phenotypic and genotypic characterization of Pediococcus strains isolated from human clinical sources. J. Clin Microbiol. April;39(4): 1241–1246.
  3. Lin J.J. 2006. Probiotics as alternative Biomedicines for pets with digestive disorders
  4. Daeschel M.A., Klaenhaemmer T.R. 1985. Association of a 13.6-megadalton plasmid in ''Pediococcus pentosaceus'' with bacteriocin activity. Appl. Environ. Microbiol. 50: 1538S-1541S
  5. (2022-02-08). "Structural Basis of Pore Formation in the Mannose Phosphotransferase System by Pediocin PA-1". Applied and Environmental Microbiology.
  6. Dalloul R.A., Lillehoj H.S, Lee J.S., Lee S.H., Chung K.S. 2006. Immunopotentiating effect of a Fomitella fraxinea – derived lectin on chicken immunity and resistance to coccidiosis. Poult. Sci. 85: 446S-451S
  7. Ennahar S., Deschamps N. 2000. Anti-Listeria effect of enoterocin A, produced by cheese-isolated ''Enterococcus faecium'' EFM01, relative to other bacteriocins from lactic acid bacteria. J.Appl. Microbiol. 88:449S-457S
  8. Lee SH, Lillehoj HS, Dalloul RA, Park DW, Hong YH, and Lin JJ. 2007. Influence of Pediococcus –based probiotic on coccidiosis in broiler chickens. Poultry Sci. 86:63-66
  9. (2020). "Probiotics (Direct-Fed Microbials) in Poultry Nutrition and Their Effects on Nutrient Utilization, Growth and Laying Performance, and Gut Health: A Systematic Review". Animals.
  10. Lee SH, Lillehoj HS, Park DW, Hong YH, and Lin JJ. 2007. Effects of Pediococcus –and Saccharomyces -based probiotic (MitoMax) on coccidiosis in broiler chickens. Comparative Immuno Microbiol & Infectious disease. 30:261-268
  11. Lin J.J. 2006. Probiotics as alternative Biomedicines for pets with digestive disorders. Proceeding of 8th Annual meeting of JBVP (Japan Board of Veterinary Practitioners). 3-288-292.
  12. Mizutani W, Yamasaki R, Lin JJ, Kuki M, and Kato G. 2007. Pediococcus-an{{sic
  13. Brady L.J., Gallaher D.D., Busta F.F. 2000. The role of probiotic cultures in the prevention of colon cancer. J. Nutr. 130: 410S–414S
  14. Cell Enumeration. 2009. Available at < http://a-.clayton.edu/furlong/BIOL3250/lab/data%20sheets/spread %20plate05.pdf> (Retrieved on November 17, 2009)
  15. Daeschel M.A., Klaenhaemmer T.R. 1985. Association of a 13.6-megadalton plasmid in Pediococcus pentosaceus with bacteriocin activity. Appl. Environ. Microbiol. 50: 1538S-1541S
  16. Ennahar S., Deschamps N. 2000. Anti-Listeria effect of enoterocin A, produced by cheese-isolated Enterococcus faecium EFM01, relative to other bacteriocins from lactic acid bacteria. J.Appl. Microbiol. 88:449S-457S
  17. Gibson G., Fuller R. 2000. Aspects of in vitro and in vivo research approaches directed towards identifying Probiotics and prebiotics for human use. The Journal of Nutrition 130:391S-395S
  18. Klaenhammer T.R. 1993. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol. Rev. 12 :39S-85S
  19. Ljungh A., Wadstrom T. 2009. Interactions of Lactobacillus with the Immune System. In: Wadstrom T, editor. Lactobacillus Molecular Biology: From genomics to Probiotics. Norfolk, UK: Caister Academic Press. p 139-147.
  20. Marteau P., de Vrese M., Cellier C., Screzenmeir J. 2001. Protection from gastrointestinal disease with the use of Probiotics. Am. J. Clin Nutr. 73: 430S-436S
  21. Mcfarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. Apr;101(4): 812-22.
  22. Media Recipe. 2009. Available at < http://www.thelabrat.com/protocols/MRSMedia.shtml> (Retrieved on November 17, 2009)
  23. Reid G., Jass J., Sebulsky M., McCormick J. (2003). Potential uses of probiotics in clinical practice. Clinical Microbiology Reviews 16: 658-672
  24. Rolfe R. 2000. The Role of probiotic cultures in the control of gastrointestinal health. The Journal of Nutrition. 130:396S-402S
  25. Sanders M.E. 2000. Considerations for use of probiotic bacteria to modulate human health. J. Nutr. 130: 384S–390S.
  26. Sanders M.E. 2007. Probiotics, strains matter. Functional foods & nutraceuticals magazine. June; pp. 36-41
  27. Sawatari Y., Tomomi H., Atsushi Y. 2008. Development of food grade media for the preparation of Lactobacillus plantarum starter culture. J. Gen. Appl. Microbiol. 52: 349S-356S
  28. Talwalkar A., Kailasapathy K. 2004. Metabolic and Biochemical Responses of Probiotic Bacteria to Oxygen. J. Dairy Sci. 86: 2537S-2546S
  29. Teitelbaum J., Walker W. 2002. Nutritional impact of pre and probiotics as protective gastrointestinal organism. Annual Review of Nutrition 22:107-138.
  30. Wollowski I., Rechkemmer G., Pool-Zobel B.L . 2001. Protective role of probiotics and prebiotics in colon cancer. Am. J. Clin. Nutr. 73: 451S–455S.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

lactobacillaceaebacteria-described-in-1887